Table 3. Major symptoms after moderate-severe COVID-19 in patient subgroups based on clinical features and treatments during COVID-19-related hospitalisation

Characteristic	Hair loss			Fatigue			Dyspnoea			Sleep difficulties
	No (n=43)	Yes (n=55)	P-value1	No (n=56)	Yes (n=42)	P-value1	No (n=65)	Yes (n=33)	P-value1	No (n=72)	Yes (n=26)	P-value1
Age, years	66 (54, 72)	58 (48, 64)	0.005	62 (51, 68)	60 (50, 66)	0.24	62 (51, 68)	56 (49, 66)	0.28	62 (50, 68)	60 (51, 65)	0.17
Sex, n (%)			0.18			0.15			0.17			0.092
Male	19 (44.2)	17 (30.9)		24 (42.8)	12 (28.6)		27 (41.5)	9 (27.3)		30 (41.7)	6 (23.1)
Female	24 (55.8)	38 (69.1)		32 (57.1)	30 (71.4)		38 (58.5)	24 (72.7)		42 (58.3)	20 (76.9)
Age group, n (%)			0.043			0.62	13 (20.0)	5 (15.2)	0.92			0.14
30–39 years	3 (7.0)	3 (5.5)		4 (7.1)	2 (4.8)		4 (6.2)	2 (6.1)		4 (5.6)	2 (7.7)
40–49 years	4 (9.3)	14 (26.2)		9 (16.1)	9 (21.4)		11 (16.9)	7 (21.2)		14 (19.4)	4 (15.4)
50–59 years	10 (23.3)	13 (23.6)		13 (23.2)	10 (23.8)		14 (21.5)	9 (27.3)		16 (22.2)	7 (26.9)
60–69 years	13 (30.2)	20 (36.4)		17 (30.4)	16 (38.1)		23 (35.4)	10 (30.3)		21 (29.2)	12 (46.2)
≥70 years	13 (30.2)	5 (9.1)		13 (23.2)	5 (11.9)
BMI, n (%)			0.040			0.72			0.26			0.74
<25 kg/m2	9 (20.9)	24 (43.6)		18 (32.1)	15 (35.7)		20 (30.8)	13 (39.4)		23 (31.9)	10 (38.5)
≥25 kg/m2	30 (69.7)	25 (45.5)		31 (55.4)	24 (57.1)		40 (61.5)	15 (45.5)		42 (58.3)	13 (50.0)
Unknown	4 (9.3)	6 (10.9)		7 (12.5)	3 (7.1)		5 (7.7)	5 (15.2)		7 (9.7)	3 (11.5)
Highest respiratory support technique during hospitalisation, n (%)			0.31			0.19			0.28			0.24
Supplemental oxygen not required	2 (4.7)	2 (3.6)		2 (3.6)	2 (4.8)		3 (4.6)	1 (3.0)		4 (5.6)	0 (0.0)
Oxygen via nasal cannula or face mask	36 (83.7)	40 (72.7)		47 (83.9)	29 (69.0)		53 (81.5)	23 (69.7)		57 (79.2)	19 (73.1)
HFNC or NIV or IMV	5 (11.6)	13 (23.6)		7 (12.5)	11 (26.2)		9 (13.8)	9 (27.3)		11 (15.3)	7 (26.9)

Values are median (interquartile range), or number of patients (%).
Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test.